ARS Pharmaceuticals, Inc. (SPRY) Misses Q3 EPS by 6c

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q3 EPS of ($0.52), $0.06 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $32.5 million versus the consensus estimate of $28.56 million.

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.

You May Also Be Interested In

• Lowe's (LOW) PT Lowered to $275 at Guggenheim
• ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04
• Dollar stores see mixed outlook ahead of earnings next week, Gordon Haskett comments